Remove Biopharma Remove Competition Remove Healthcare
article thumbnail

Health Economics and Outcomes Research: Biopharma’s Underappreciated Value Creator

MedCity News

The way ahead for HEOR in biopharma should be built on increasing C-suite visibility and understanding of the value contribution that HEOR makes and demonstrating that a failure to invest in HEOR puts companies at a competitive disadvantage, especially in the face of rising regulatory and payer expectations for evidence.

Biopharma 263
article thumbnail

Which Healthcare Startups Won the MedCity INVEST Pitch Perfect Contest?

MedCity News

The competition saw 23 healthcare startups across biopharma, medical devices, and health tech geared for consumers/employers as well as payers/providers pitch their business plans to teams of investor judges.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovation key for boosting UK biopharma competitiveness

European Pharmaceutical Review

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.

article thumbnail

Biogen Bows Out of Acorda Pact on MS Med; Focus Turns to New Growth Drivers

MedCity News

Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.

article thumbnail

Harnessing the Power of Generational Diversity as a Competitive Advantage

PM360

As professionals with more than a half-century between us working in biopharma and diagnostics marketing and communications from the corporate (Ayaz Malik) and agency (Sandra Stahl) sides, we believe nurturing multigenerational teams is an especially powerful yet underutilized strategy for our industry. To be sure, steps have been taken.

article thumbnail

The perfect storm is coming for pharma

World of DTC Marketing

Eight US antitrust bills targeting the pharmaceutical industry have been recently introduced, addressing a gamut of alleged anti-competitive activity. Senator Amy Klobuchar has proposed the Competition and Antitrust Law Enforcement Reform Act. Financial Times.

Pharma 187
article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

Embarking on the journey from product development to market success in the biopharma industry is no small feat. The landscape is highly competitive with new prescription medications launching worldwide each year. However, this journey is fraught with challenges as revealed by an in-depth analysis.